Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story in Immunics SEC paperwork can feel like decoding clinical data all over again. Each 10-K weaves together R&D expenses, trial outcomes, and cash 80 2runway projections, while 8-K updates surface overnight with new cohort results or capital raises. If you have ever typed 93Immunic SEC filings explained simply 94 or hunted for 93Immunic insider trading Form 4 transactions, 94 you know how time 80 2consuming this search can be.
Stock Titan solves that problem. Our AI reads every page the moment it hits EDGAR, delivering 93understanding Immunic SEC documents with AI 94 in minutes. Receive concise briefs that connect the dots between pipeline milestones and balance sheet risk, and jump directly to tables that matter 80whether you need the latest 93Immunic quarterly earnings report 10-Q filing, 94 an 93Immunic annual report 10-K simplified, 94 or 93Immunic 8-K material events explained. 94 Real 80 1time alerts flag 93Immunic Form 4 insider transactions real-time, 94 so you can monitor 93Immunic executive stock transactions Form 4 94 without refreshing EDGAR.
Why does it matter? For a clinical 80 2stage biotech, dilution, cash usage, and trial disclosures drive valuation. Our platform highlights when IMU 80 838 moves into Phase 3, where milestone payments appear in the proxy, and how non 80 2cash charges affect EPS in each 93Immunic earnings report filing analysis. 94 You also get quick links to 93Immunic proxy statement executive compensation 94 to understand incentives behind strategic choices. With AI 80 powered summaries, expert context, and instantaneous updates, you 99ll never miss the disclosure that moves Immunic 99s share price.
Immunic (Nasdaq: IMUX) disclosed that it received a Nasdaq bid-price deficiency notice after its shares closed below $1.00 for 30 consecutive trading days, violating Listing Rule 5450(a)(1).
The company has 180 calendar days, until December 24 2025, to regain compliance by posting a closing bid of at least $1.00 for ten consecutive business days. If unsuccessful, Immunic may seek a second grace period or effect a reverse stock split; failure would result in delisting.
The notice does not immediately affect the stock’s listing on the Nasdaq Global Select Market. Management is monitoring the price and evaluating options.
This Form 4/A amends a previously filed Form 4 for Jason Tardio, President and COO of Immunic (IMUX), correcting an administrative error in reported stock option grants from June 5, 2025.
Key transactions reported:
- Purchase of 12,512 shares of common stock at $0.79 per share
- Grant of 598,500 stock options at an exercise price of $0.7729, expiring June 5, 2035
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. This amendment corrects the number of stock options originally reported in the June 9, 2025 filing.
Immunic CFO Glenn Whaley filed an amended Form 4 (Form 4/A) to correct a previously reported stock option grant from June 5, 2025. The amendment addresses an administrative error in the number of options reported in the original filing dated June 9, 2025.
Key details of the corrected transaction:
- Granted 503,500 stock options at an exercise price of $0.7729 per share
- Options expire on June 5, 2035
- Vesting schedule: 25% vests after one year, with remaining vesting monthly over 36 months
The direct ownership of these derivative securities provides long-term equity incentive alignment between the CFO and shareholders. The relatively low exercise price suggests the company's stock may be trading at modest levels, though this grant represents a significant equity position for a C-level executive.
Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025. The amendment addresses two significant transactions:
- Stock Purchase: Acquired 15,000 shares of common stock at $0.77 per share on June 4, 2025, bringing direct ownership to 29,000 shares
- Stock Option Grant: Received 1,558,000 stock options on June 5, 2025, with an exercise price of $0.7729, expiring June 5, 2035
The options vest 25% after one year, with remaining shares vesting monthly over 36 months. Vitt also maintains indirect ownership of 362,877 shares through Listrax UG, where he serves as Managing Director. The amendment specifically corrects an administrative error regarding the number of stock options granted in the original filing.
Immunic has filed a Form 4/A (amended insider trading report) for Executive Chairman and Director Duane Nash, correcting a previously filed Form 4 from June 9, 2025. The amendment addresses an administrative error in the reported number of stock options granted.
Key details of the transaction:
- Transaction Date: June 5, 2025
- Granted 570,000 stock options to purchase common stock
- Exercise price: $0.7729 per share
- Options expire on June 5, 2035
- Vesting schedule: Monthly increments over one year from grant date
This filing represents a significant equity compensation grant to a senior executive, with the options having a 10-year exercise period. The relatively low exercise price and substantial option quantity suggests a strong alignment of management interests with shareholders.
This Form 4/A amends a previously filed Form 4 for Andreas Muehler, Chief Medical Officer of Immunic (IMUX), correcting an administrative error in reported stock option grants.
Key details of the amended filing:
- Transaction Date: June 5, 2025
- Grant of 598,500 stock options at exercise price of $0.7729 per share
- Options expire on June 5, 2035
- Vesting Schedule: 25% after first year, remaining 75% monthly over next 36 months
The amendment was necessary to correct the number of stock options granted, which was incorrectly reported in the original Form 4 filed on June 9, 2025. The options represent a significant equity compensation package for the CMO, with a ten-year exercise window.
FAQ
What is the current stock price of Immunic (IMUX)?
What is the market cap of Immunic (IMUX)?
What is the primary focus of Immunic Inc?
How does IMU-838 work?
Which diseases are targeted by Immunic's pipeline?
What differentiates Immunic’s approach from traditional therapies?
What is the role of IMU-856 in Immunic's portfolio?
How does Immunic ensure scientific credibility?
What market needs does Immunic address?
How is Immunic positioned within the biopharmaceutical industry?
